LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

Description

This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surrounding normal tissues.

Conditions

Anaplastic Ependymoma, Ependymoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surrounding normal tissues.

Pilot Trial of LET Optimized IMPT for Pediatric Patients With Ependymoma

LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

Condition
Anaplastic Ependymoma
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States, 02114

Houston

M D Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Previous pathologic confirmation of ependymoma, World Health Organization (WHO) grade II or III
  • * Disease must be confined to the brain (no evidence of spread on MR imaging of the spine or on staging lumbar puncture)
  • * Patient may not receive chemotherapy concurrent with radiation
  • * Signed informed consent by patient and/or parents or legal guardian
  • * Lansky performance status score of 50 -100
  • * Patients with previous radiation therapy to the brain
  • * Ependymoma of the spine
  • * Disseminated ependymoma requiring craniospinal radiation therapy
  • * Pregnancy
  • * Inability to undergo MR imaging
  • * Inability to receive gadolinium-based contrast agent

Ages Eligible for Study

to 22 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

M.D. Anderson Cancer Center,

David R Grosshans, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2027-12-31